0001104659-23-071772.txt : 20230615 0001104659-23-071772.hdr.sgml : 20230615 20230615210033 ACCESSION NUMBER: 0001104659-23-071772 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230613 FILED AS OF DATE: 20230615 DATE AS OF CHANGE: 20230615 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Patel Sushil CENTRAL INDEX KEY: 0001860609 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38596 FILM NUMBER: 231019169 MAIL ADDRESS: STREET 1: C/O REPLIMUNE GROUP, INC. STREET 2: 500 UNICORN PARK, THIRD FLOOR CITY: WOBURN STATE: MA ZIP: 01801 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Replimune Group, Inc. CENTRAL INDEX KEY: 0001737953 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 822082553 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 BUSINESS ADDRESS: STREET 1: 500 UNICORN PARK CITY: WOBURN STATE: MA ZIP: 01801 BUSINESS PHONE: (781) 222-9600 MAIL ADDRESS: STREET 1: 500 UNICORN PARK CITY: WOBURN STATE: MA ZIP: 01801 4 1 tm2318878-1_4seq1.xml OWNERSHIP DOCUMENT X0407 4 2023-06-13 0 0001737953 Replimune Group, Inc. REPL 0001860609 Patel Sushil C/O REPLIMUNE GROUP, INC. 500 UNICORN PARK DRIVE WOBURN MA 01801 0 1 0 0 Chief Strategy Officer 1 Common Stock 2023-06-13 4 S 0 5145 24.11 D 149426 D Common Stock 2023-06-13 4 S 0 553 23.44 D 148873 D The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on March 15, 2023, that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.80 to $24.54. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.29 to $23.53. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Following the sales reported on this form 4, the reporting person continues to beneficially own 148,873 shares of the Issuer's common stock. The reporting person also holds options to acquire an aggregate of 263,750 shares of the Issuer's common stock, 88,072 of which are exercisable as of the date hereof. /s/ Shawn Glidden, attorney-in-fact 2023-06-15